Skip to main content Accessibility help
×
Home
Hostname: page-component-768ffcd9cc-8zwnf Total loading time: 0.59 Render date: 2022-12-04T02:26:49.860Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

16 - The ependymal route for central nervous system gene therapy

Published online by Cambridge University Press:  04 November 2009

Erica Butti
Affiliation:
Neuroimmunology Unit San Raffaella Scientific Institute–DIBIT Via Olgettina 58 20132 Milano Italy
Gianvito Martino
Affiliation:
Neuroimmunology Unit San Raffaele Scientific Institute–DIBIT Via Olgettina 58 20132 Milano Italy
Roberto Furlan
Affiliation:
Neuroimmunology Unit San Raffaele Scientific Institute–DIBIT Via Olgettina 58 20132 Milano Italy
Turgut Tatlisumak
Affiliation:
Helsinki University Central Hospital
Marc Fisher
Affiliation:
University of Massachusetts Medical School
Get access

Summary

Introduction

Therapies targeting the central nervous system (CNS) are a crucial challenge for future medicine. In fact, degenerative and immune-mediated disorders of the CNS are a major threat to quality of life in the elderly, but diseases affecting the brain are also not infrequent in infancy and adult life. Transfer of recent progresses in the knowledge of molecular mechanisms involved in the pathogenesis of neurological disorders into novel therapies is difficult, because penetration of molecules into the brain is extremely limited by the presence of the blood–brain barrier (BBB). The BBB is characterized by tight junctions between endothelial cells which are impermeable to macromolecules and even ions, and by reduced endothelial endocytic activity that considerably decreases the number of molecules that can cross the BBB in a non-specific fashion. Most of conventional therapeutic agents effective in the CNS are supposed to cross the BBB because of their small size. However, more than 98% of small molecules cannot cross the BBB either, and only the presence of specific transport mechanisms assures that molecules essential for the brain metabolism (e.g., amino acids and glucose) reach the brain parenchyma. Thus, by employing conventional administration routes (i.e., oral, intravenous, intramuscular), which share the bloodstream as the final driving force to the brain, both rate and selectivity of the drug delivery are severely hampered, resulting in limited efficacy and potential side effects.

Type
Chapter
Information
Handbook of Experimental Neurology
Methods and Techniques in Animal Research
, pp. 257 - 268
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Pardridge, WM. Targeting neurotherapeutic agents through the blood–brain barrier. Arch Neurol. 2002, 59: 35.CrossRefGoogle ScholarPubMed
Pardridge, WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002, 36: 555–558.CrossRefGoogle ScholarPubMed
Furlan, R, Pluchino, S, Martino, G. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. Curr. Opin. Neurol. 2003, 16: 385–392.CrossRefGoogle ScholarPubMed
Miranda, SR, Erlich, S, Friedrich, VL Jr, Gatt, S, Schuchman, EH. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann–Pick disease. Gene Ther. 2000, 7: 1768–1776.CrossRefGoogle Scholar
Leimig, T, Mann, L, Martin, M, , del P, et al. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood. 2002, 99: 3169–3178.CrossRefGoogle ScholarPubMed
Matzner, U, Hartmann, D, Lullmann-Rauch, R, et al. Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther. 2002, 9: 53–63.CrossRefGoogle Scholar
Burton, EA, Fink, DJ, Glorioso, JC. Gene delivery using herpes simplex virus vectors. DNA Cell Biol. 2002, 21: 915–936.CrossRefGoogle ScholarPubMed
Zurn, AD, Henry, H, Schluep, M, et al. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant. 2000, 9: 471–484.CrossRefGoogle ScholarPubMed
Davidson, BL, Breakefield, XO. Viral vectors for gene delivery to the nervous system. Nature Rev. Neurosci. 2003, 4: 353–364.CrossRefGoogle Scholar
Janson, C, McPhee, S, Bilaniuk, L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV–2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 2002, 13: 1391–1412.CrossRefGoogle ScholarPubMed
Martino, G, Furlan, R, Comi, G, Adorini, L. The ependymal route to access the central nervous system: an emerging immuno-gene therapy approach to multiple sclerosis. Trends Immunol. 2001, 22: 483–490.CrossRefGoogle Scholar
Shimamura, M, Sato, N, Oshima, K, et al. Therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 2004, 109: 424–431.CrossRefGoogle ScholarPubMed
Furlan, R, Brambilla, E, Ruffini, F, et al. Intrathecal delivery of IFNγ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of CNS-infiltrating lymphocytes. J. Immunol. 2001, 167: 1821–1829.CrossRefGoogle Scholar
Poliani, PL, Brok, H, Furlan, R, et al. Delivery of a non-replicative herpes simplex type-1 vector engineered with the IL-4 gene to the central nervous system protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum. Gene Ther. 2001, 12: 905–920.CrossRefGoogle Scholar
Burton, EA, Glorioso, JC, Fink, DJ. Therapy progress and prospects: Parkinson's disease. Gene Ther. 2003, 10: 1721–1727.CrossRefGoogle ScholarPubMed
Martino, G, Furlan, R, Galbiati, F, et al. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Mult. Scler. 1998, 4: 222–227.Google ScholarPubMed
Furlan, R, Poliani, PL, Galbiati, F, et al. Central nervous system delivery of Interleukin-4 by a non replicative Herpes Simplex Type I viral vector ameliorates autoimmune demyelination. Hum. Gene Ther. 1998, 9: 2605–2617.CrossRefGoogle ScholarPubMed
Ruffini, F, Furlan, R, Poliani, PL, et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gen Ther. 2001, 8: 1207–1213.CrossRefGoogle ScholarPubMed
Furlan, R, Poliani, PL, Marconi, PC, et al. Interleukin-4 gene delivery in the central nervous system at the time of disease onset inhibits progression of autoimmune demyelination. Gen. Ther. 2001, 8: 13–19.CrossRefGoogle Scholar
Thomas, CE, Schiedner, G, Kochanek, S, Castro, MG, Lowenstein, PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first generation, but not with high-capacity, adenovirus vectors: towards realistic long-term neurological gene therapy for chronic diseases. Proc. Natl Acad. Sci. USA 2000, 97: 7482–7487.CrossRefGoogle ScholarPubMed
Schiedner, G, Morral, N, Parks, RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 1998, 18: 180–183.CrossRefGoogle ScholarPubMed
Parks, RJ, Chen, L, Anton, M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre mediated excision of the viral packaging signal. Proc. Natl Acad. Sci. USA 1996, 93: 13565–13570.CrossRefGoogle ScholarPubMed
Bukovsky, AA, Song, JP, Naldini, L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 1999, 73: 7087–7092.Google ScholarPubMed
High, KA. Gene transfer as an approach to treating hemophilia. Circ. Res. 2001, 88: 137–144.CrossRefGoogle ScholarPubMed
Muzyczka, N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 1992, 158: 97–129.Google ScholarPubMed
Duan, D, Li, Q, Kao, AW, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristic responsible for long-term episomial persistence in muscle tissue. J. Virol. 1999, 73: 8568–8577.Google Scholar
Nakai, H, Iwaki, Y, Kay, MA, Couto, LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junction from mouse liver. J. Virol. 1999, 73: 5438–5447.Google Scholar
Ueda, H, Amano, H, Shiomi, H, Takagi, H. Comparison of the analgesic effects of various opioid peptides by a newly devised intracisternal injection technique in conscious mice. Eur. J. Pharmacol. 1979, 56: 265–268.CrossRefGoogle Scholar
Furlan, R, Pluchino, S, Marconi, PC, Martino, G. Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. Methods Mol. Biol. 2003, 215: 279–289.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×